The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Cellular mechanisms and treatments for chemobrain: insight from aging and neurodegenerative diseases
Open accessAbstract
Chemotherapy is a life-saving treatment for cancer patients, but also causes long-term cognitive impairment, or "chemobrain", in survivors. However, several challenges, including imprecise diagnosis criteria, multiple confounding factors, and unclear and heterogeneous molecular mechanisms, impede effective investigation of preventions and treatments for chemobrain. With the rapid increase in the number of cancer survivors, chemobrain is an urgent but unmet clinical need. Here, we leverage the extensive knowledge in various fields of neuroscience to gain insights into the mechanisms for chemobrain. We start by outlining why the post-mitotic adult brain is particularly vulnerable to chemotherapy. Next, through drawing comparisons with normal aging, Alzheimer's disease, and traumatic brain injury, we identify universal cellular mechanisms that may underlie the cognitive deficits in chemobrain. We further identify existing neurological drugs targeting these cellular mechanisms that can be repurposed as treatments for chemobrain, some of which were already shown to be effective in animal models. Finally, we briefly describe future steps to further advance our understanding of chemobrain and facilitate the development of effective preventions and treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adult Neurogenesis in the Mammalian Brain: Significant Answers and Significant Questions
Ming, G.-L., & Song, H. (2011) · Neuron · doi:10.1016/j.neuron.2011.05.001 · Cited by 2,651 · cited 2×
“Adult neurogenesis occurs primarily in niche regions: the subgranular zone (SGZ) of the dentate gyrus of the hippocampus, the subventricular zone (SVZ) lining the lateral ventricles (Ming & Song, 2011), and the striatum (Ernst et al , 2014).”
Hoeijmakers, J. H. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804615 · Cited by 2,239
The Diagnosis and Management of Mild Cognitive Impairment: A Clinical Review
Langa, K. M., & Levine, D. A. (2014) · JAMA · doi:10.1001/jama.2014.13806 · Cited by 1,337 · cited 13×
“A gradual loss of spines and dendrites also occurs in aging (Dickstein et al , 2013), AD (Dorostkar et al , 2015), and TBI (Gao et al , 2011; Przekwas et al , 2016).”
InfluentialMotor skill learning requires active central myelination
McKenzie, I. A., Ohayon, D., Li, H., Paes de Faria, J., Emery, B., Tohyama, K., & Richardson, W. D. (2014) · Science · doi:10.1126/science.1254960 · Cited by 1,177
Proinflammatory Cytokines, Aging, and Age-Related Diseases
Michaud, M., Balardy, L., Moulis, G., Gaudin, C., Peyrot, C., Vellas, B., Cesari, M., & Nourhashemi, F. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.05.009 · Cited by 1,094 · cited 1×
“There is a common consensus that chronic neuroinflammation is responsible for maintaining long-term cognitive dysfunctions in aging and neurodegenerative diseases (Glass et al , 2010; Michaud et al , 2013).”
Stress weakens prefrontal networks: molecular insults to higher cognition
Arnsten, A. F. T. (2015) · Nature Neuroscience · doi:10.1038/nn.4087 · Cited by 752 · cited 1×
“For example, dysregulated calcium/cyclic adenosine monophosphate (cAMP) signaling, such as during stress, can lead to spine destabilization and loss (Arnsten, 2015).”
Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation
Lima Giacobbo, B., Doorduin, J., Klein, H. C., Dierckx, R. A. J. O., Bromberg, E., & de Vries, E. F. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1283-6 · Cited by 750
Minocycline selectively inhibits M1 polarization of microglia
Kobayashi, K., Imagama, S., Ohgomori, T., Hirano, K., Uchimura, K., Sakamoto, K., Hirakawa, A., Takeuchi, H., Suzumura, A., Ishiguro, N., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.54 · Cited by 742
Inflammation: the link between comorbidities, genetics, and Alzheimer’s disease
Newcombe, E. A., Camats-Perna, J., Silva, M. L., Valmas, N., Huat, T. J., & Medeiros, R. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1313-3 · Cited by 532 · cited 1×
“Similarly, activated microglia and astrocytes are observed in many mouse models of AD, often predating the onset of cognitive abnormalities (Newcombe et al , 2018).”
Establishment of axon-dendrite polarity in developing neurons.
Barnes, A. P., & Polleux, F. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.31.060407.125536 · Cited by 523
Update on Alzheimer’s Disease Therapy and Prevention Strategies
Graham, W. V., Bonito-Oliva, A., & Sakmar, T. P. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-103753 · Cited by 506 · cited 1×
“For AD, a decrease in acetylcholine is frequently observed, which explains why three out of four FDA-approved drugs for treating AD are acetylcholinesterase inhibitors (Graham et al , 2017).”
Dagher, N. N., Najafi, A. R., Kayala, K. M. N., Elmore, M. R. P., White, T. E., Medeiros, R., West, B. L., & Green, K. N. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0366-9 · Cited by 505
Dendritic structural plasticity and neuropsychiatric disease
Forrest, M. P., Parnell, E., & Penzes, P. (2018) · Nature Reviews Neuroscience · doi:10.1038/nrn.2018.16 · Cited by 464
Gibson, E. M., Nagaraja, S., Ocampo, A., Tam, L. T., Wood, L. S., Pallegar, P. N., Greene, J. J., Geraghty, A. C., Goldstein, A. K., Ni, L., et al. (2019) · Cell · doi:10.1016/j.cell.2018.10.049 · Cited by 372 · cited 3×
“Two additional studies showed that microglia, astrocytes, and oligodendrocytes are all dysregulated following methotrexate treatment (Geraghty et al , 2019; Gibson et al , 2019).”
Han, R., Yang, Y. M., Dietrich, J., Luebke, A., Mayer-Pröschel, M., & Noble, M. (2008) · Journal of Biology · doi:10.1186/jbiol69 · Cited by 316
Targeting Oxidative Stress in Central Nervous System Disorders
Patel, M. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.06.007 · Cited by 312 · cited 1×
“Fourth, the post-mitotic brain accounts for ~ 2% of the body-weight, but consumes ~ 20% of glucose-derived energy (Patel, 2016), resulting in a high production of reactive oxygen species (ROS) — a major source of DNA damage.”
Impaired Cognitive Function and Hippocampal Neurogenesis following Cancer Chemotherapy
Christie, L.-A., Acharya, M. M., Parihar, V. K., Nguyen, A., Martirosian, V., & Limoli, C. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2000 · Cited by 311 · cited 2×
“Similarly, cyclophosphamide or doxorubicin treatment did not change the number of BrdU-positive cells, but reduced the number of DCX-positive and doubly labeled BrdU/ NeuN cells (Christie et al , 2012), suggesting that both the early and late maturation phases were affected.”
Cognitive Training for Improving Executive Function in Chemotherapy-Treated Breast Cancer Survivors
Kesler, S., Hadi Hosseini, S. M., Heckler, C., Janelsins, M., Palesh, O., Mustian, K., & Morrow, G. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.02.004 · Cited by 300 · cited 1×
“…current clinical approach is to refer cancer survivors to psychiatrists who can prescribe cognitive rehabilitation, changes to lifestyle, mind-training exercises, cognitive – behavioral therapy, and general coping strategies (Ferguson et al , 2012; Kesler et al , 2013; Henneghan & Harrison, 2015).”
Dendritic spine changes associated with normal aging
Dickstein, D. L., Weaver, C. M., Luebke, J. I., & Hof, P. R. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.077 · Cited by 289
Chen, X., Hu, Y., Cao, Z., Liu, Q., & Cheng, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02122 · Cited by 288
Analyzing dendritic spine pathology in Alzheimer’s disease: Problems and opportunities
Dorostkar, M. M., Zou, C., Blazquez-Llorca, L., & Herms, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1449-5 · Cited by 235
Hains, A. B., Vu, M. A. T., Maciejewski, P. K., van Dyck, C. H., Gottron, M., & Arnsten, A. F. T. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908563106 · Cited by 234 · cited 1×
“Hyperactivation of protein kinase C underlies the reduction in dendritic complexity and cognitive impairment in aging and chronic psychological stress (Hains et al , 2009; Brudvig & Weimer, 2015), suggesting that inhibition of protein kinase C is a promising therapeutic strategy.”
Howard, R., Zubko, O., Bradley, R., Harper, E., Pank, L., O’Brien, J., Fox, C., Tabet, N., Livingston, G., Bentham, P., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3762 · Cited by 194
The role of neuromodulators in selective attention
Noudoost, B., & Moore, T. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.10.006 · Cited by 161
Alzheimer’s disease and hippocampal adult neurogenesis; exploring shared mechanisms
Hollands, C., Bartolotti, N., & Lazarov, O. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00178 · Cited by 160
Phoumthipphavong, V., Barthas, F., Hassett, S., & Kwan, A. C. (2016) · eneuro · doi:10.1523/eneuro.0133-15.2016 · Cited by 132
Anti-Inflammatory Impact of Minocycline in a Mouse Model of Tauopathy
Garwood, C. J., Cooper, J. D., Hanger, D. P., & Noble, W. (2010) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2010.00136 · Cited by 106 · cited 1×
“However, findings about minocycline’s effects in animal models of AD and TBI have been mixed, ranging from beneficial to harmful (Garwood et al , 2010; Ferretti et al , 2012; Yang et al , 2012; Scott et al , 2018).”
Peripheral Chemo-Cytokine Profiles in Alzheimers and Parkinsons Diseases
Reale, M., Greig, N., & Kamal, M. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709789055199 · Cited by 82
Cited by
Multiple early factors anticipate post-acute COVID-19 sequelae
Su, Y., Yuan, D., Chen, D. G., Ng, R. H., Wang, K., Choi, J., Li, S., Hong, S., Zhang, R., Xie, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.014 · Cited by 1,156
“Future studies of other ‘‘long’’ medical conditions, such as post-treatment Lyme disease (Rebman and Aucott, 2020), ‘‘chemobrain’’ (Nguyen and Ehrlich, 2020), and postICU syndrome (Brown et al.”
Mechanisms of Chemotherapy-Induced Neurotoxicity
Was, H., Borkowska, A., Bagues, A., Tu, L., Liu, J. Y. H., Lu, Z., Rudd, J. A., Nurgali, K., & Abalo, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.750507 · Cited by 285
Haller, O. J., Semendric, I., George, R. P., Collins-Praino, L. E., & Whittaker, A. L. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105120 · Cited by 13
“exercising may help to ameliorate the condition, there are currently no recommended therapeutic treatment strategies for CICI (Nguyen and Ehrlich, 2020).”
Background
Metadata
- Authors
- Nguyen, L. D., & Ehrlich, B. E.
- Venue
- EMBO Molecular Medicine
- Published
- 2020-04-29
- Volume
- 12
- Issue
- 6
- Pages
- e12075-e12075
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W3019023480
- Cited by
- 175
- References
- 28
- FWCI
- 10.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.